Biomedical Advanced Research and Development Authority (BARDA)

RRPV has released a Request for Information (RFI) to identify organizations with artificial intelligence capabilities that can support the discovery and advancement of broad-spectrum, small-molecule therapeutics targeting filoviruses, including Ebola, Sudan, and Marburg viruses. This RFI seeks information on technical capabilities, infrastructure, relevant experience, and innovative approaches for applying AI and advanced computational methodologies across the therapeutic development lifecycle. Areas of interest include AI-driven therapeutic design, in vitro hit verification, and early preclinical proof-of-concept evaluation. Respondents do not need to be members of the RRPV consortium to participate. Responses are due Wednesday, Jun. 17 at 1 p.m. ET. Learn more: https://lnkd.in/giv6cDuv #RRPV #Opportunity #RFI

🚨 Deadline Extended 🚨   The submission deadline for the Rapid Antibody Production for Immunoassay Diagnostics Request for Project Proposals (RPP) has been extended to Monday, May 18 at 12 p.m. ET.   This funding opportunity will advance the research and development of rapid antibody or other protein-based molecular recognition reagent generation platforms. These platforms would support timely production of immunoassay-ready reagents to detect pathogens for eventual diagnostic use.     This RPP is seeking highly flexible, rapidly adaptable systems capable of generating high-performance binders against both known pathogens and emerging biological threats during public health emergencies.   Learn more and view the posted Q&A here: https://lnkd.in/ePsd95ru #RRPV #Opportunity #Solicitation

Registration is now open for RRPV’s On-Demand Manufacturing (ODM) for Therapeutic Biologics Workshop! 📢 This one-day, in-person event will bring together leaders from industry and government to explore the evolving landscape of ODM for therapeutic biologics. Attendees will hear from expert speakers, connect directly with government stakeholders through 1:1 conversations, and participate in guided roundtable discussions to foster collaboration, share insights, and identify pathways for future partnerships. 📅 When: May 21, 2026 📍 Where: Crystal Gateway Marriott | Arlington, VA Learn more and register to secure your spot today: https://lnkd.in/e35EcEu9 ⚠️ Note: This event is limited to relevant organizations within RRPV or the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium to ensure meaningful participation and alignment with workshop goals. #RRPV #Event #Biomanufacturing #Innovation

𝗙𝗶𝗻𝗮𝗹 𝘄𝗲𝗲𝗸 𝘁𝗼 𝗮𝗽𝗽𝗹𝘆! The Concept Stage submission deadline for the SMART Antiviral Prize is Monday, May 11, 2026. With up to 3 reserved pathways into Stage 1 and an expanded Stage 1 prize pool, the path forward for Concept Stage applicants is even stronger. If you’re planning to apply, this is the moment to finalize your submission — focusing on clarity, alignment with evaluation criteria, and a well-defined approach. Submit your application and review final details here: https://lnkd.in/egc2jSik

Antimicrobial resistance (AMR) and biothreats are threats to national health security. Drug-resistant bacteria can turn common infections into deadly ones, particularly for patients recovering after a chemical, biological, radiological, or nuclear (CBRN) incident. A critical aspect of emergency preparedness is the availability of effective antibiotics to treat infections caused by AMR and biothreat pathogens. To help address this challenge, BARDA awarded a new Project BioShield contract to Shionogi Inc. (U.S.) to support the late-stage development of cefiderocol for the treatment of certain biothreat infections. This partnership will also support onshoring of manufacturing of this antibiotic. By investing in both innovation and onshoring, we are protecting vulnerable patients, securing our medical supply chain, and reinforcing national preparedness against future health emergencies. Learn more: https://lnkd.in/guZzmTzK

The FebriDx Bacterial/Non-Bacterial Assay from our partner, Lumos Diagnostics, is the 110th BARDA-supported product to receive U.S. Food and Drug Administration (FDA) approval, licensure, or clearance. This dual 510(k) clearance and CLIA-waiver expands use of this test to settings such as doctor’s offices, retail clinics, and pharmacies. This rapid diagnostic detects host biomarkers in blood collected from a fingerstick, provides results after 10 minutes, and helps determine if a patient’s acute respiratory infection is caused by a bacterial infection. It can inform health care decisions and reduce unnecessary or inappropriate antibiotic use. This helps ensure patients can get fast and accurate diagnoses and treatment and has the potential to improve #AntibioticStewardship. This program's success demonstrates the value of collaborative #PublicPrivatePartnerships between the U.S. government and product development partners to combat antimicrobial resistance (#AMR). Learn more: https://lnkd.in/gMfxrKKA

Preparing your SMART Antiviral Prize Concept Stage submission? To make the process easier, we’ve consolidated key Concept Stage resources in one place, so you can quickly find what you need as you develop and refine your submission. Here’s where to start: 𝗗𝗲𝘀𝗶𝗿𝗲𝗱 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗔𝘁𝘁𝗿𝗶𝗯𝘂𝘁𝗲𝘀: Guidance to help shape and position your concept 🔗 https://lnkd.in/eDHrnrgw 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗼𝗰𝗲𝘀𝘀 & 𝗖𝗿𝗶𝘁𝗲𝗿𝗶𝗮: An overview of how submissions are reviewed and what reviewers are looking for 🔗 https://lnkd.in/eDRtqi7X 𝗙𝗔𝗤𝘀 & 𝗥𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀: Answers to common questions and additional program context 🔗 https://lnkd.in/eN9VfQUF Whether you’re still assessing fit or already working through your application, these materials are designed to help you align your approach and prepare a strong submission. With the May 11 deadline approaching, now is a good time to review the details and make sure everything is in place. Explore all resources and begin your application here: https://lnkd.in/eaXGvzXr 

BARDA is pleased to announce the reopening of the Flexible and Strategic Therapeutics (FASTx) solicitation. FASTx aims to advance the development of cost-effective, adaptable therapeutic platforms to accelerate our response to emerging biological threats. Of particular interest are modular antiviral platforms, such as peptide-drug conjugates, targeted protein degraders, and lipid-drug conjugates, with the capacity to target a diverse set of viral families. Proposals must advance a filovirus candidate and include options for a second candidate against another HHS priority threat. Key requirements include: ✔️Demonstrated in vitro efficacy of a candidate against one or more filoviruses. ✔️A plan to advance candidates through in vivo efficacy and pharmacokinetic assessment. Learn more here: https://ow.ly/XJsU50YO4mH To request a pre-submission call, please contact FASTxBAA@hhs.gov

📢 Request for Project Proposals (RPP) Released: Rapid Antibody Production for Immunoassay Diagnostics    RRPV has released a new opportunity to advance the research and development of rapid antibody or other protein-based molecular recognition reagents generation platforms. The platforms would support timely production of immunoassay-ready reagents to detect pathogens for eventual diagnostic use. This RPP seeks highly flexible, rapidly adaptable systems capable of generating high-performance binders against pathogens, both known or previously unknown biological threats during public health emergencies.  Proposed solutions should demonstrate advanced capabilities in protein and binder design and discovery, including computational, AI-enabled, and high-throughput experimental approaches, integrated with downstream optimization and a clear pathway to GMP production.  Holistic, end-to-end solutions are sought for this requirement. A Proposers Conference and Teaming Connect for the Rapid Antibody Production for Immunoassay Diagnostics (RAPID) RPP will be held on Monday, April 27th at 11:00AM ET. Proposals are due May 13, 2026 at 1:00 PM ET. Explore the full RPP and Proposer’s Conference details. 👇   https://lnkd.in/eysgQx6p #RRPV #Opportunity #Solicitation 

Still have questions about the SMART Antiviral Prize? Join our 𝗙𝗜𝗡𝗔𝗟 𝗦𝗠𝗔𝗥𝗧 𝗔𝗻𝘁𝗶𝘃𝗶𝗿𝗮𝗹 𝗣𝗿𝗶𝘇𝗲 𝗜𝗻𝗳𝗼 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗼𝗻 𝗔𝗽𝗿𝗶𝗹 𝟮𝟭 — the last opportunity to get clarity before the Concept Stage submission deadline on May 11. In this session, we’ll cover: • Prize scope and scientific focus • Eligibility and solution areas • Evaluation criteria and key dates • Practical guidance for preparing your submission You’ll also have the opportunity to engage directly with the VITAL team during a live Q&A. If you’re currently preparing your application or finalizing your approach this session is designed to help you move forward with greater clarity. Register here 👉 https://luma.com/aubb13ap